Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. saw a notable increase in stock performance today, contrasting with the broader market trends. Despite recent gains and a strong weekly performance, the company faces challenges such as low Return on Capital Employed and a high Debt to Equity ratio, indicating potential long-term financial hurdles.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Over the past week and month, the stock has faced notable decreases. Despite a modest annual gain, the company struggles with high debt levels and negative returns on equity, indicating ongoing challenges.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. faced a significant stock decline, contrasting with the minor decrease in the China Shanghai Composite. Despite a slight weekly increase, Dizal's longer-term performance shows an 8.97% drop over the past month and concerns over profitability and financial stability persist.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. faced a significant stock decline amid a challenging market, reaching an intraday low. Despite a weekly gain, its one-month performance remains negative. Concerns about financial health are highlighted by low profitability metrics and a high debt-to-equity ratio, indicating potential long-term growth issues.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. saw a significant intraday increase on March 10, 2026, outperforming the China Shanghai Composite. However, its longer-term performance reveals challenges, with declines over the past month and year-to-date. Key financial metrics indicate concerns regarding the company's financial health.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. saw a significant intraday gain today, contrasting with the modest rise of the China Shanghai Composite. However, its longer-term performance reveals declines over the past week, month, and year-to-date, alongside concerning financial indicators and a high debt-to-equity ratio.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Over the past week, the company has faced a notable downturn, with year-to-date and one-year returns lagging behind the market. Financial metrics indicate challenges in management efficiency and stability.

Dizal (Jiangsu) Pharmaceutical Co., Ltd. saw a notable stock decline today, contrasting with the broader market's performance. Over the past month, the company has faced significant challenges, including a decrease in stock value and concerns regarding management efficiency and high debt levels, raising questions about its growth potential.